Application of optimal design methodologies in clinical pharmacology experiments

Pharmaceutical Statistics

Volumn 8, Issue 3, 2009, Pages 239-252

  Ogungbenro, Kayode ^a   Dokoumetzidis, Aristides ^a   Aarons, Leon ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Mixed effects modelling; Optimal design; Population fisher information matrix; Population pharmacokinetics; Sampling windows

Indexed keywords

DRUG;

BAYES THEOREM; CLINICAL PHARMACOLOGY; CLINICAL PRACTICE; CLINICAL STUDY; DRUG DESIGN; DRUG MONITORING; DRUG RESEARCH; PEDIATRICS; PHARMACODYNAMICS; POPULATION RESEARCH; PROCESS OPTIMIZATION; REVIEW; STATISTICAL MODEL;

ANIMALS; HUMANS; PHARMACOLOGY, CLINICAL; RESEARCH DESIGN;

EID: 73349129984     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.354     Document Type: Review

References (77)

1. Holford NH, Sheiner LB. Kinetics of pharmacologic response. Pharmacology and Therapeutics 1982; 16:143-166.
2. Duffull SB. Design of clinical pharmacology trials. Clinical and Experimental Pharmacology and Physiology 2001; 28:905-912.
3. Sheiner LB. Learning versus confirming in clinical drug development. Clinical Pharmacology and Therapeutics 1997; 61:275-291.
4. Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. Journal of Pharmacokinetics and Pharmacodynamics 2003; 30:387-404.
5. Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods. Journal of Pharmacokinetics and Pharmacodynamics 2003; 30:405-416.
6. Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall SA, Benincosa LJ, Tensfeldt TG, Parivar K, Amantea M, Glue P, Koide H, Miller R. Model-based drug development. Clinical Pharmacology and Therapeutics 2007; 82:21-32.
7. FDA, US Department of Health and Human Services. Innovation or Stagnation? Challenge and Opportunity on the Critical Path to New Medical Products, US Department of Health and Human Services, Food and Drug Administration, 2004.
8. Aarons L. Population pharmacokinetics: theory and practice. British Journal of Clinical Pharmacology 1991; 32:669-670.
9. Aarons L. Population pharmacokinetics. International Journal of Clinical Pharmacology, Therapeutics and Toxicology 1992; 30:520-522.
10. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics 1977; 5:445-479.
11. Atkinson Jr AJ, Lalonde RL. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview. Clininical Pharmacology and Therapeutics 2007; 82:3-6.
12. Vozeh S, Steimer JL, Rowland M, Morselli P, Mentré F, Balant LP, Aarons L. The use of population pharmacokinetics in drug development. Clinical Pharmacokinetics 1996; 30:81-93.
13. Holford NH, Kimko HC, Monteleone JP, Peck CC. Simulation of clinical trials. Annual Review of Pharmacology and Toxicology 2000; 40:209-234.
14. Mentré F, Mallet A, Baccar D. Optimal design in random-effects regression models. Biometrika 1997; 84:429-442.
15. Davidian M, Giltinan DM. Nonlinear models for repeated measurement. Chapman and Hall: London, 1995.
16. Retout S, Mentré F. Optimization of individual and population designs using Splus. Journal of Pharmacokinetics and Pharmacodynamics 2003; 30:417-443.
17. Retout S, Mentré F. Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics. Journal of Biopharmaceutical Statistics 2003; 13:209-227.
18. Gagnon R, Leonov S. Optimal population designs for PK models with serial sampling. Journal of Biopharmaceutical Statistics 2005; 15:143-163.
19. Gueorguieva I, Aarons L, Ogungbenro K, Jorga KM, Rodgers T, Rowland M. Optimal design for multivariate response pharmacokinetic models. Journal of Pharmacokinetics and Pharmacodynamics 2006; 33:97-124.
20. Gueorguieva I, Ogungbenro K, Graham G, Glatt S, Aarons L. A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models. Computer Methods and Programs in Biomedicine 2007; 86:51-61.
21. Bazzoli C, Retout S, Mentre F. Population design evaluation and optimisation for multiple responses models: application to the pharmacokinetics of AZT and AZT-TP 2. Fundamental and Clinical Pharmacology 2007; 21:9-9.
22. Retout S, Duffull S, Mentré F. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Computer Methods and Programs in Biomedicine 2001; 65:141-151.
23. Ogungbenro K, Graham G, Gueorguieva I, Aarons L. Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experiments. Journal of Biopharmaceutical Statistics 2008; 18:342-358.
24. Ogungbenro K, Gueorguieva I, Majid O, Graham G, Aarons L. Optimal design for multiresponse pharmacokinetic-pharmacodynamic models: dealing with unbalanced designs. Journal of Pharmacokinetics and Pharmacodynamics 2007; 34:313-331.
25. Foracchia M, Hooker A, Vicini P, Ruggeri A. POPED, a software for optimal experiment design in population kinetics. Computer Methods and Programs in Biomedicine 2004; 74:29-46.
26. Hooker A, Vicini P. Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments. AAPS Journal 2005; 7:E759-E785.
27. al Banna MK, Kelman AW, Whiting B. Experimental design and efficient parameter estimation in population pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1990; 18:347-360.
28. Wang J, Endrenyi L. A computationally efficient approach for the design of population pharmacokinetic studies. Journal of Pharmacokinetics and Biopharmaceutics 1992; 20:279-294.
29. Atkinson AC, Donev AN. Optimum experimental designs. Oxford University Press: Oxford, 1992.
30. Atkinson AC, Chaloner K, Herzberg AM, Juritz J. Optimum experimental designs for properties of a compartmental model. Biometrics 1993; 49:325-337.
31. Merle Y, Mentré F. Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model. Journal of Pharmacokinetics and Biopharmaceutics 1995; 23:101-125.
32. Tod M, Rocchisani JM. Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1997; 25:515-537.
33. Retout S, Mentré F, Bruno R. Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics. Statistics in Medicine 2002; 21:2623-2639.
34. Fedorov VV, Hackl P. Model-oriented design of experiments. Springer: New York, 1997.
35. Ogungbenro K, Graham G, Gueorguieva I, Aarons L. The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments. Computer Methods and Programs in Biomedicine 2005; 80:115-125.
36. Duffull SB, Retout S, Mentré F. The use of simulated annealing for finding optimal population designs. Computer Methods and Programs in Biomedicine 2002; 69:25-35.
37. Aarons L, Balant LP, Mentré F, Morselli PL, Rowland M, Steimer JL, Vozeh S. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. European Journal of Clinical Pharmacology 1996; 49:251-254.
38. Jonsson EN, Wade JR, Karlsson MO. Comparison of some practical sampling strategies for population pharmacokinetic studies. Journal of Pharmacokinetics and Biopharmaceutics 1996; 24:245-263.
39. Hashimoto Y, Sheiner LB. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis. Journal of Pharmacokinetics and Biopharmaceutics 1991; 19:333-353.
40. Pronzato L. Information matrices with random regressors. Application to experimental designs. Journal of Statistical Planning and Inference 2002; 108:189-200.
41. Duffull SB, Mentré F, Aarons L. Optimal design of a population pharmacodynamic experiment for ivabradine. Pharmaceutical Research 2001; 18:83-89.
42. Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. British Journal of Clinical Pharmacology 2003; 56:96-103.
43. Green B, Duffull SB. Prospective evaluation of a D-optimal designed population pharmacokinetic study. Journal of Pharmacokinetics and Pharmacodynamics 2003; 30:145-161.
44. Waterhouse TH, Redmann S, Duffull SB, Eccleston JA. Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients. Journal of Pharmacokinetics and Pharmacodynamics 2005; 32:521-545.
45. Hennig S, Waterhouse TH, Bell SC, France M, Wainwright CE, Miller H, Charles BG, Duffull SB. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. British Journal of Clinical Pharmacology 2007; 63:438-450.
46. Graham G, Aarons L. Optimal blood sampling time windows for parameter estimation in population pharmacokinetic experiments. Statistics in Medicine 2006; 25:4004-4019.
47. Patan M, Bogacka B. Efficient sampling windows for parameter estimation in mixed-effects models. In mODa 8 - Advances in Model-Oriented Design and Analysis, López-Fidalgo J, Rodríguez-Díaz JM, Torsney B (eds). Physica-Verlag: Heidelberg, 2007; 147-155.
48. Bogacka B, Johnson P, Jones B, Volkov O. D-efficient window experimental designs. Journal of Statistical Planning and Inference 2008; 138:160-168.
49. Ogungbenro K, Aarons L. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments. Journal of Biopharmaceutical Statistics submitted.
50. Retout S, Mentré F. Population Design Optimisation: PFIMOPT 1.0, 2005.
51. Duffull S, Eccleston J, Kimko H, Denman NG. WinPOPT user guide. University of Otago: Dunedin, 2006. http://www.winpopt.com/.
52. Mentré F, Duffull S, Guorguieva I, Hooker A, Leonov S, Ogungbenro K, Retout S. Software for optimal design in population pharmacokinetics and pharmacodynamics: a comparison. PAGE: Copenhagen, Denmark, 2007.
53. Atkinson AC, Bogacka B. Compound D- and D-s-optimum designs for determining the order of a chemical reaction. Technometrics 1997; 39:347-356.
54. Cook RD, Wong WK. On the equivalence of constrained and compound optimal designs. Journal of the American Statistical Association 1994; 89:687-692.
55. Dokoumetzidis A, Aarons L. Bayesian optimal designs for pharmacokinetic models: sensitivity to uncertainty. Journal of Biopharmaceutical Statistics 2007; 17:851-867.
56. Nguyen L, Tranchand B, Puozzo C, Variol P. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. British Journal of Clinical Pharmacology 2002; 53:459-468.
57. Bos AME, Boom K, Vinks AA, Boezen HM, Wanders J, Dombernovsky P, Aamdal S, de Vries EGE, Uges DRA. Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755. Cancer Chemotherapy and Pharmacology 2004; 54:64-70.
58. d'rgenio DZ, Schumitzky A. ADAPT II user's guide: pharmacokinetics and pharmacodynamics systems analysis software. Biomedical simulation resource. University of Southern California, Los Angeles, 1997.
59. Chenel M, Ogungbenro K, Duval V, Laveille C, Jochemsen R, Aarons L. Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial. Journal of Pharmacokinetics and Pharmacodynamics 2005; 32:737-756.
60. Reed MD. Optimal sampling theory: an overview of its application to pharmacokinetic studies in infants and children. Pediatrics 1999; 104:627-632.
61. Abdel-Rahman SM, Reed MD, Wells TG, Kearns GL. Considerations in the rational design and conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls. Clinical Pharmacology and Therapeutics 2007; 81:483-494.
62. Meibohm B, Laer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS Journal 2005; 7.
63. Panetta JC, Iacono LC, Adamson PC, Stewart CF. The importance of pharmacokinetic limited sampling models for childhood cancer drug development. Clinical Cancer Research 2003; 9:5068-5077.
64. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997; 276:122-126.
65. West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999; 284:1677-1679.
66. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clinical Pharmacokinetics 2006; 45:931-956.
67. Symcyp. Simcyp Limited, Sheffield, UK, 2008.
68. PK-Sim. PK-Sim, Bayer Technology, 2008.
69. Mentré F, Dubruc C, Thenot JP. Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children. Journal of Pharmacokinetics and Pharmacodynamics 2001; 28:299-319.
70. Burstein AH, Gal P, Forrest A. Evaluation of a sparse sampling strategy for determining vancomycin pharmacokinetics in preterm neonates: application of optimal sampling theory. Annals of Pharmacotherapy 1997; 31:980-983.
71. Stass H. Determination of minimal sampling time points for reliable pharmacokinetic evaluation of recombinant factor VIII - an exploratory population pharmacokinetic analysis in paediatric patients suffering from severe haemophilia. Haemophilia 2006; 12:50-55.
72. Mahmood I. Limited sampling model for the estimation of pharmacokinetic parameters in children. Therapeutic Drug Monitoring 2000; 22:532-536.
73. Mahmood I, Tammara V. A comparison of two sparse sampling population pharmacokinetic approaches for the estimation of pharmacokinetic parameters in children. International Journal of Clinical Pharmacology and Therapeutics 2004; 42:240-245.
74. Panetta JC, Wilkinson M, Pui CH, Relling MV. Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia. Journal of Pharmacokinetics and Pharmacodynamics 2002; 29:171-188.
75. Beringer P, Aminimanizani A, Synold T, Scott C. Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. Therapeutic Drug Monitoring 2002; 24:315-321.
76. Sheiner LB, Beal S, Rosenberg B, Marathe VV. Forecasting individual pharmacokinetics. Clinical Pharmacology and Therapeutics 1979; 26: 294-305.
77. Merle Y, Mentré F, Mallet A, Aurengo AH. Designing an optimal experiment for Bayesian estimation: application to the kinetics of iodine thyroid uptake. Statistics in Medicine 1994; 13:185-196.